跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 555 条关于
“M1/M4 muscarinic”
全部
555
临床试验
257
药物
63
机构
0
资讯
235
去年
MapLight Therapeutics Initiates Phase 2 Trial of Novel M1/M4 Muscarinic Agonist ML-007C-MA for Schizophrenia Treatment
8个月前
MapLight Therapeutics Receives FDA Fast Track Designation for Alzheimer's Disease Psychosis Treatment
去年
Cobenfy Shows Cognitive Benefits in Schizophrenia Patients with CANTAB Assessment
9个月前
Syremis Therapeutics Launches with $165M Series A to Advance Novel Mental Health Therapies
2年前
BMS Acquires Karuna Therapeutics for $14 Billion, Betting on Novel Schizophrenia Drug KarXT
24天前
FDA Clears IND for Neurocrine and Nxera's Oral M1 Agonist NBI-1117567 in Alzheimer's Cognition
去年
Xanomeline/Trospium Chloride (COBENFY™) Approved for Schizophrenia Treatment
去年
Bristol Myers Squibb Presents New COBENFY Data for Schizophrenia Treatment at Psych Congress
2个月前
First In Vivo PET Evidence Reveals Widespread M1 Receptor Deficits in Living Schizophrenia Patients
去年
Bristol Myers Squibb Soars as AbbVie's Schizophrenia Drug Fails Trial
第 1 页,共 24 页
上一页
下一页